There is mounting evidence that decorin inhibits the growth of various tumor cell lines when either overexpressed in vitro or provided as a recombinant protein.
Introduction
Decorin is a prototype member of an expanding family of small leucine-rich proteoglycans, ubiquitous molecules characterized by 10 ± 12 tandem arrays of leucinerich repeats (Iozzo, 1997 (Iozzo, , 1998 . The decorin protein core folds into an arch-shaped structure capable of interacting with various extracellular matrix proteins, growth factors and their receptors (Weber et al., 1996) . Targeted deletion of the decorin gene (Danielson et al., 1997) and bitransgenic animals with de®ciency of both decorin and p53 (Iozzo et al., 1999a) have provided genetic evidence for a role of decorin in matrix assembly and tumorigenesis, respectively. The results of these studies have con®rmed and corroborated earlier observations implicating decorin protein core in modulating collagen ®brillogenesis (Vogel et al., 1984) and cell growth via a block of TGF-b 1 activity .
Our working hypothesis is that decorin represents a natural antagonist of tumor growth. This hypothesis is based on several key observations that have shown a marked elevation of decorin expression within the tumor stroma of colon cancer (Adany et al., 1990) , an increased decorin gene transcription in serumstarved and quiescent cells (Coppock et al., 1993; Mauviel et al., 1995) , and a marked suppression of decorin gene expression in most viral-or spontaneously-transformed cells (Coppock et al., 1993; Adany et al., 1990) . Moreover, decorin expression is dierentially down-regulated in hepatocellular carcinomas (Miyasaka et al., 2001) and in *70% of ovarian carcinomas and ovarian cancer cells (Shridhar et al., 2001 ) as compared to their normal counterparts.
The mechanism of action of decorin has only recently begun to be elucidated by the discovery that decorin is a novel biological ligand of the EGFR (Moscatello et al., 1998; Patel et al., 1998; Iozzo et al., 1999b) . This interaction with the EGFR diers from that induced by EGF, since decorin leads to a protracted down-regulation of EGFR tyrosine kinase (CsordaÂ s et al., 2000) , and other members of the ErbB family of receptor tyrosine kinase , and causes an attenuation of the EGFR-mediated mobilization of intracellular calcium (CsordaÂ s et al., 2000) . The decorin/EGFR interaction induces the expression of the endogenous cyclin-dependent kinase inhibitor p21
WAF1 (De Luca et al., 1996) and a subsequent arrest of the cells in the G1 phase of the cell cycle . These cytostatic eects of decorin occur in a wide variety of tumor cell lines with a diverse histogenetic background (Santra et al., 1997; Nash et al., 1999) and can also aect murine tumor cells (Santra et al., 1997) and normal cells such as endothelial cells (SchoÈ nherr et al., 2001 ) and macrophages (Xaus et al., 2001) .
Because decorin is a highly soluble compound, and because the activity of decorin occurs in an autocrine and paracrine fashion, we sought to determine whether adenovirus-mediated gene delivery into solid tumors could aect the behavior of the tumor xenografts. We demonstrate that transient transgene expression of replication-de®cient adenovirus-containing decorin causes a signi®cant growth inhibition of colon carcinoma and squamous carcinoma tumor xenografts. The cytostatic eects of decorin correlated with a markedly reduced proliferative index and an attenuation of the EGFR phosphorylation in vivo. Thus, decorin gene therapy helps in retarding the growth of human tumors in immunocompromised animals and could represent a new independent or adjunctive therapeutic modality against cancer.
Results

Efficient transduction of various tumor cell lines with Ad-Dcn
To determine whether Ad-Dcn was capable of eciently transducing WiDr and A431 tumor cells, we added increasing amounts of Ad-Dcn vector or empty vector, and determined decorin expression by Northern blotting. The results showed a signi®cant expression of the virally-transduced decorin gene transcript, a single *1.9 kb band (Figure 1a ), whose levels increased in a dose-dependent manner. In agreement with previous results Moscatello et al., 1998) , no decorin message was detected in either control tumor cell (Figure 1a ). Real time PCR showed that the expression of the decorin transcript was time-dependent in A431 cells (Figure 1b) , and could also be demonstrated in Cos-7 and HeLa cells (Figure 1c) . Moreover, following a 48 hincubation, the message levels induced by Ad-Dcn were higher than those induced by a bacterial expression vector (pcDNA) harboring the potent CMV promoter (not shown). Western immunoblotting showed signi®cant production of decorin proteoglycan (Figure 1d ), a *100-kDa broad band, with a migration similar to that described before for stable expressing clones of WiDr and A431 , and typical of recombinant decorin proteoglycan (Hocking et al., 1998; Ramamurthy et al., 1996; Mann et al., 1990) . To further con®rm the biological activity of decorin, we reacted Ad-Dcntransduced cells with a monoclonal antibody (mAb E12120) that speci®cally recognizes the phosphorylated (activated) form of the EGFR. The results showed a marked suppression of the EGFR phosphorylation in the A431 cells when compared to either control (no virus) or the empty viral vector ( Figure  1e ). Thus, our Ad-Dcn vector is capable of inducing high levels of decorin expression that can be detected at least 10 days after transduction in several cell lines. Moreover, decorin is biologically active since it can down-regulate the EGFR kinase as in stably transfected tumor cell lines (CsordaÂ s et al., 2000; .
Suppression of tumor growth by direct intra-neoplastic injection of Ad-Dcn
The high eciency of transduction and the relatively high levels of transgene expression mediated by the adenoviral vector in cultured cells prompted us to investigate the anti-oncogenic properties of decorin in vivo by direct intra-neoplastic injection of the Ad-Dcn. To this end, we performed two sets of experiments. In the ®rst set of experiments, animals were injected s.c. with a relatively large inoculum of tumor cells (2610 6 cells/animal), and the mice were observed for 5 ± 7 days until a palpable tumor of *30 mm 3 emerged. At this time, each tumor xenograft was directly injected with 50 ml of PBS containing 7610 7 pfu of either AdDcn or empty viral vector. A second treatment was done 4 ± 5 days later. Interestingly, in both WiDr ( Figure 2a ) and A431 (Figure 2b ) tumor xenografts there was a signi®cant reduction of tumor growth (P50.02). However, the eect was rather transient since the slope of the curve was nearly identical in both treated and untreated animals at later times. In addition, because of the large inoculum size, the growth rate of both xenografts was very rapid and, thus, several tumors in both groups had necrotic centers, thereby preventing an accurate assessment of the decorin's eects.
In a second set of experiments we tried to duplicate a more clinically relevant situation by injecting smaller inocula, and by treating the preestablished tumor xenografts with higher doses and multiple injections of recombinant Ad-Dcn. The results showed a marked inhibition of tumor growth in both the colon carcinoma ( Figure 2c ) and squamous carcinoma (Figure 2d ) xenograft models. In both cases, a progressive inhibition of tumor burden was observed. At the end of the experiments, the decrease in tumor volume for the Ad-Dcn-treated colon carcinoma xenografts reached 67% (P50.001) (Figure 2c ), and 52% inhibition (P50.002) for the squamous carcinoma xenografts (Figure 2d ). Thus, topical delivery of AdDcn has substantial cytostatic eects in two animal models of aggressive human tumors.
Adenoviral-mediated expression of decorin causes morphological changes in tumor xenografts
We studied the morphology of the tumor xenografts generated with smaller inocula and multiple Ad-Dcn injections. While the wild-type WiDr showed solid tumors ( Figure 3a) with invasion of the deep fascia and skeletal muscle (not shown), the Ad-Dcn-treated neoplasms showed well demarcated margins ( Figure  3b ) and often showed areas of glandular dierentiation ( Figure 3c ). Similarly, the A431 squamous carcinoma xenografts showed invading margins (Figure 3d ), whereas the Ad-Dcn-treated counterparts showed sharp, non-invading borders (Figure 3e ), and areas of squamous dierentiation characterized by the formation of numerous keratin pearls ( Figure 3f ). Thus, the decorin-induced growth inhibition is also associated (Fisher et al., 1995) . The migration of pre-stained molecular weight markers is shown in the right margin. (e) Immuno¯uorescence staining of A431 squamous carcinoma cells following transduction for 72 h with Ad-Dcn at the designated concentrations, control (no virus) or empty vector, using a monoclonal antibody directed against the phosphorylated form of the EGFR (BD Transduction Laboratories). Cells were ®xed for 15 min in 3% paraformaldehyde, permeabilized for 10 min with digitonin, and incubated with the primary antibody (1 : 500). Slides were washed and incubated with secondary goat anti-mouse IgG-FITC (1 : 1000) antibody. Immuno¯uorescence was performed on an Olympus IX70 inverted epi¯uorescence microscope coupled to a high quantum eciency cooled CCD camera. The four panels were exposed for the same amount of time. Notice the signi®cant reduction in EGFR signal in both decorin-transduced cells. Scale bar=50 mm with changes in the architecture and dierentiation of the tumor xenografts.
Decorin gene expression correlates with a decreased proliferative index and an attenuation of EGFR activation
Next, we sought to determine whether decorin gene transfer would correlate with a reduced proliferative index and a reduced activation of the EGFR. To test these possibilities we stained tumor samples with antibodies directed against Ki-67, an established proliferation marker, and a monoclonal antibody (mAb E12120) that speci®cally recognizes the phosphorylated (activated) form of the EGFR (see above). There was a marked reduction of the Ki-67 staining in the treated tumor xenografts (Figure 4b,d ) as compared to the vector controls (Figure 4a,c) . To obtain the proliferative index, we estimated the percentage of tumor cell nuclei positive for Ki-67 marker in 10 highpower (6400) ®elds per animal (n=3 animals per group). The proliferative index for the WiDr and A431 controls was 36+6% and 28+5%, respectively (mean+s.e.m.). In contrast, in the Ad-Dcn-treated samples, the Ki-67 proliferative index was 6+2% and 5+3%, respectively (P50.001 in both cases).
The staining for the activated EGFR was also diminished in the treated samples (Figure 4f ,h) when compared to vector controls (Figure 4e,g ). In the WiDr xenografts there was a linear staining outlining the cellular contours (Figure 4e ). In agreement with their high content of EGFR, A431 cells reacted more intensely with the anti-EGFR antibody. Figure 4g shows a pocket of intensely-stained A431 tumor cells just below the unreactive mouse epidermis. These data are also in agreement with the in vitro data shown in Figure 1e .
When the tumor xenografts were reacted with a polyclonal antibody speci®c for the N-terminal peptide of the human decorin protein core, we detected decorin epitopes in pericellular pools mostly located near the periphery of the tumor xenografts (Figure 4j,l) , while the vector controls were unreactive (Figure 4i,k) .
Collectively, these results provide strong evidence for the in vivo anti-proliferative eects of decorin and suggest that, at least in part, decorin inhibits the proliferation of tumor cells by interfering with EGFR activity. 
Discussion
The inhibitory eects of decorin on TGF-b activity have been exploited in experimental glomerulonephritis (Isaka et al., 1996) , atherosclerosis (Fischer et al., 2001) , lung morphogenesis (Zhao et al., 1999) , and pulmonary ®brosis (Kolb et al., 2001) . This is the ®rst report of a successful in vivo treatment of two human xenograft models using adenovirus-mediated decorin gene transfer. The results showed a marked inhibition of tumor growth in both the colon and squamous carcinoma xenograft models. In both cases, a progressive inhibition of tumor burden was observed. In AdDcn-treated colon carcinoma xenografts this reduction was greater than squamous carcinoma xenografts (67% versus 52% of control values) but in both cases the dierence was statistically signi®cant with P values 50.001 and 50.002, respectively). We should point out that the total amount of Ad-Dcn injected is still below what has been used in most animal experiments and recent clinical trials. In fact, the highest total dose/ animal (see Figure 2c ) reached 7610 8 pfu/22 g (the average weight of a nu/nu mouse), or equivalent to a dose of *3.2610 10 pfu/kg in a human. Thus, topical delivery of Ad-Dcn has a signi®cant cytostatic eect in two animal models of aggressive human tumors.
Interestingly, adenoviral-mediated expression of decorin caused morphological changes in the human tumor xenografts. These changes included sharper border, reduced invasiveness, reduced angiogenesis and evidence of cyto-dierentiation. Whether these changes are the direct results of decorin treatment or a consequence of reduced tumor growth is not clear, but it warrants future investigation. The morphologic appearance of the transduced tumors is reminiscent of that obtained with xenografts produced by coinjection of wild-type and decorin-expressing A431 cells (CsordaÂ s et al., 2000) . In the latter case, tumors grew only when the ratio of wild-type to decorin-expressing cells was quite high (51 : 2), and in the tumors generated at lower (1 : 4 or 1 : 8) ratios there was evidence of cyto-dierentiation and sharper, noninvasive tumor boundaries. Thus, the Ad-Dcn vector can produce eects similar to those induced by a constant source of decorin derived from the stably expressing tumor cell clones . The present study extends these observations and supports the feasibility of decorin gene transfer in a clinically relevant setting, either as primary or combined therapy. The latter possibility is supported by the synergistic action of decorin and carboplatin in the in vitro inhibition of human ovarian cancer cells (Nash et al., 1999) .
Human carcinomas frequently express high levels of EGFR and over-expression of EGFR and ErbB2 has been correlated with a more aggressive phenotype (Carpenter, 2000) . Accordingly, therapeutic modalities directed at preventing the function of these receptors have been pursued as useful anti-cancer treatments (Mendelsohn and Baselga, 2000) . A key ®nding of our study is that decorin gene expression in the treated tumor xenografts correlated well with a decreased proliferative index and an attenuation of EGFR activation. The latter observation is a novel and important ®nding since this is the ®rst report that decorin gene delivery alters EGFR activity in vivo. There is strong genetic evidence to support this important pathway of EGFR inactivation (Moghal and Sternberg, 1999; Carraway and Sweeney, 2001 ). In Drosophila melanogaster, for instance, there is a protein, named Kekkon1 (Musacchio and Perrimon, 1996) , that acts in a feedback loop to negatively regulate the Drosophila EGFR during oogenesis (Ghiglione et al., 1999) . Kekkon1 contains six leucine-rich repeats homologous to decorin and accumulates in the dorsal-anterior follicle cells in an EGFR-dependent manner (Ghiglione et al., 1999; Musacchio and Perrimon, 1996) . Notably, loss and gain of Kekkon1 augments or suppresses EGFR activity, respectively, and the two proteins interact physically when co-expressed in cells (Ghiglione et al., 1999) . These ®ndings suggest a model where Kekkon1 may interfere with ligand activation or may facilitate the negative regulation of EGFR following activation (Carraway and Sweeney, 2001) . It is likely that mammalian cells may also utilize similar leucine-rich structures to counteract the EGFR. In contrast to Kekkon1, which is a trans-membrane protein and, thus, able to interact only with EGFR molecules on the same or adjacent cells, the soluble decorin could diuse distantly and potentially interact with numerous target cells expressing varying levels of EGFR.
While adenovirus vectors induce immuno-reactivity in humans, thereby limiting their multiple use, other gene delivery systems, such as adenovirus associated viral vectors, are being rapidly developed. Thus, we believe that the safe and repeatable gene transfer of decorin-containing viral vectors could represent a novel therapeutic tool against cancer. There are a number of advantages of using decorin as a primary or adjuvant therapy. Decorin, being a secreted proteoglycan, could interact with a number of cell-surface receptors at distant sites of transduction (Iozzo, 1999) . Conceivably, a single decorin-transduced cell could aect several neighboring cells, thereby rendering this therapeutic modality eective even in systems with low or unpredictable transduction eciency. An increase in decorin content in the pericellular environment of solid tumors, such as colon and squamous carcinomas, could trigger a functional interaction with the EGFR and other members of the ErbB family of receptor tyrosine kinase, thereby initiating a signaling cascade Figure 4 Expression of Ki-67, activated EGFR and decorin in WiDr colon carcinoma and A431 squamous carcinoma xenografts treated with either empty adenoviral vector (Control) or Ad-Dcn. (a ± d) Representative photomicrographs of sections stained with a mouse monoclonal antibody (B126.1) against the nuclear proliferation marker Ki-67 (Biomeda Corp.), used at 1 : 100 dilution. Notice the markedly reduced number of cells with positive nuclear staining in the Ad-Dcn treated samples. (e ± h) Representative photomicrographs of sections stained with a mouse monoclonal antibody (E12120) raised against the activated (phosphorylated form) of the human EGFR (Transduction Laboratories), used at 1 : 500 dilution. Notice the linear staining outlining the contours of WiDr cells (e) and the markedly diminished staining in the Ad-Dcn-treated xenograft (f). In A431 xenografts there is a more intense staining because of the large number of EGFRs (1 ± 2610 6 receptors/cell) expressed by these neoplasic cells. Notice the presence of a strongly reactive group of tumor cells just below the unreactive mouse epidermis (g) and the diminished reactivity in the Ad-Dcn treated tumor xenograft. (h). (i ± l), representative photomicrographs of sections stained with a rabbit anity-puri®ed antiserum raised against the N-terminal peptide of human decorin (Fisher et al., 1995) , used at 1 : 500 dilution. Notice the mostly perpendicular deposits of decorin-containing epitopes only in the Ad-Dcn treated xenografts (j and l). Scale bars=140 mm that would lead to growth retardation or arrest. Decorin is a natural product and, therefore, there should not be any immune response to it. Moreover, over-expression of decorin has profound cytostatic eects preferentially on malignant cells independent of their histogenetic origin (Santra et al., 1997) . At least in vitro, smooth muscle cells appear to react dierently to decorin, primarily by responding to the decorin-mediated block of TGF-b activity (Fischer et al., 2001) , while in macrophages recombinant decorin can enhance cell survival (Xaus et al., 2001) . Thus, although the pleiotropic eects of decorin need to be elucidated in future studies, our results provide support to the hypothesis that decorin could be used as a therapeutic modality to combat cancer, either as a primary or an adjuvant compound. The lack of toxicity, its solubility and its mode of action, i.e. an action on multiple cells and at a distance, make decorin gene therapy an attractive mode of intervention for numerous forms of human malignancy.
Materials and methods
Cell lines, antibodies and adenovirus production
Human WiDr colon carcinoma, A431 squamous carcinoma cells, 293 embryonic kidney cells, HeLa squamous cell carcinoma and monkey Cos-7 cells were obtained from the American Type Culture Collection. The following antibodies were used: a monoclonal antibody (E12120) raised against the activated (phosphorylated form) of the human EGFR (BD Transduction Laboratories); a rabbit anity-puri®ed antiserum raised against the N-terminal peptide of human decorin (Fisher et al., 1995) ; a mouse monoclonal antibody (B126.1) against the nuclear proliferation marker Ki-67 (Biomeda Corp., Foster City, CA, USA). Full-length human decorin cDNA was cloned into a shuttle vector containing the human CMV promoter and the E1 region of the human adenovirus type 5 genome. The recombinant adenovirusdecorin (Ad-Dcn) was generated by homologous recombination after co-transfection with the shuttle vector and a virusrescuing vector as described before (Zhao et al., 1999) . Samples of both decorin and control vectors were stepampli®ed in increasing sizes of low passage 293 cells, using successive rounds of freezing and thawing, and centrifugation. High titers of Ad-Dcn or empty vector were puri®ed by CsCl density gradient ultracentrifugation and chromatography on pre-packed G-25 columns. Puri®ed viruses were plaque titered in 293 cells and expressed as plaque-forming units (pfu). Alternatively, virus was puri®ed with the Viraprep Kit (Virapur, Carlsbad, CA, USA), and viral titer was determined by TCID 50 assay.
Viral transduction, Northern blotting, real time PCR and immunofluorescence
WiDr and A431 cells were cultured in a 6-well tray. While sub-con¯uent, , and 1610 6 pfu) was added to the media. Cells were grown for 2 ± 10 days without media change before harvesting for RNA. In addition, Cos-7 and HeLa squamous carcinoma cells were transduced. As a further control, human decorin cDNA in pcDNA3 plasmid (Invitrogen, Carlsbad, CA, USA) was transfected in cells using Transit LT-1 (PanVera, Madison, WI, USA), Cells were drained of media and RNA was extracted with Tri Reagent (Sigma, St. Louis, MO, USA). RNA was run on a 1% agarose gel with 10% formaldehyde in 16 MOPS and stained with ethidium bromide for photography. RNA was transferred onto a nylon membrane (Osmonics, Westborough, MA, USA) and cross-linked with UV Strata linker (Stratagene, Cedar Creek, TX, USA). A human decorin cDNA probe was produced by PCR of full-length human decorin cDNA. Forward primer AAGAACCTTCACG-CATTG and reverse primer TCCAACTACAGAGATATT were used to generate a 611 bp fragment which was labeled with 32 P-dCTP using the Random Primer DNA Label System (Life Technologies, Rockville, MD, USA). Blots were hybridized with a radio-labeled probe in 1 M NaH 2 PO 4 at pH 7.2, 1 mM EDTA, 7% SDS, and 1% BSA overnight, thoroughly washed, and exposed to ®lm for 2 ± 4 h at room temperature. Reverse transcription reaction was performed on RNA with SuperScript II Reverse Transcriptase (Life Technologies, Rockville, MD, USA). Real time PCR was carried out on samples as per manufacturer's protocols (Applied Biosystems 7700 ABI Prism Sequence Detector) using forward primer AGTGACTTCTGCCCACCCTGG and reverse primer CCGGGTTGCTGAAAAGACTC. Quantization of message was based on standard DNA curve generated with known quantities of human decorin cDNA. For immuno¯uorescence, cells were cultured in chamber slides (Nunc, Napervile, IL, USA), and, while sub-con¯uent, they were transduced with adenoviral decorin (1610 5 pfu and 2610 5 pfu) or control vector (2610 5 pfu) for 72 h. Following a 15 min ®xation in 3% paraformaldehyde, the cells were permeabilized for 10 min with digitonin (30 mg/ml), blocked with 1% BSA for 1 h, and incubated for 30 min with the primary antibody (1 : 500) against the phosphorylated (activated) form of the human EGFR (BD Transduction Laboratories, Franklin Lakes, NJ, USA). Slides were washed with 1% BSA and incubated with secondary goat anti-mouse IgG-FITC antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) at a 1 : 1000 dilution for 30 min. Immuno¯uorescence microscopy was performed on an Olympus IX70 inverted epi¯uorescence microscope coupled to a high quantum eciency cooled CCD camera. Digital images were imported into Adobe 1 Photoshop 6.0.
Animal experimemts, morphology and immunohistochemistry
Animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication number 85-23) and the Institutional Animal Care and Use Committee of Thomas Jeerson University. Human colon and squamous cell carcinoma xenografts were established in athymic nude nu/nu mice, 6 ± 8 weeks of age (Charles River Laboratories) through subcutaneous inoculation of 0.5 ± 2610 6 cells into the dorsal¯ank of each mouse. Mice were carefully examined every 2 or 3 days and any tumor growth was measured with a micro-caliper according to the following formula: V=a (b 2 /2), where a and b represent the larger and smaller diameters, respectively. When tumors had reached 2 ± 3 mm in greater diameter, each mouse received direct intra-neoplastic injections (*50 ml containing 0.7 ± 1610 8 pfu) of replication-incompetent adenovirus, either empty virus or virus harboring the full-length decorin gene. Student's two-sided t-test was used to compare the values of the treated and control samples. A value of P50.05 was considered as signi®cant.
Animals were sacri®ced at the end of the experiments, between 19 and 58 days depending on the treatment regimen and inoculum size, and each tumor was carefully dissected. The tumors were ®xed in 10% buered formaldehyde, embedded in paran and processed for routine histology. For immunohistochemistry, sections placed on poly-L-lysinecoated glass slides were de-paranized, and epitope retrieval was performed in 10 mM EDTA buer for 10 min in a microwave at 600 W, or by incubating the slides with pepsin for 10 min. After epitope retrieval, endogenous peroxidase was blocked in 0.03% H 2 O 2 , washed in PBS and incubated with the primary antibodies diluted between 1 : 100 and 1 : 500. The peroxidase-labeled polymer conjugated to either goat anti-rabbit or anti-mouse method (DAKO EnVision+ System, DAKO Corp., Carpinteria, CA, USA) was used to detect antigen-antibody reaction. Speci®c reactions were visualized with 3,3'-diaminobenzidine as a chromogen and images were captured with a Pixera digital camera and processed using Adobe 1 Photoshop 6.0. To determine the proliferative index of tumor xenografts, we estimated the percentage of tumor cell nuclei positive for Ki-67 marker in 10 high-power (6400) ®elds per animal (n=3 animals per group). Additional details are provided in the legends to ®gures.
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